JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC

DURING 2025, JCHR WAS ENGAGED IN 61 CLINICAL STUDIES, WHICH CULMINATED IN 53 SCIENTIFIC PUBLICATIONS AND 58 PRESENTATIONS AT PROMINENT NATIONAL AND INTERNATIONAL CONFERENCES. IN 2025, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (6), HELMSLEY CHARITABLE TRUST (7), BREAKTHROUGH T1D (5), FOUNDATION FIGHTING BLINDNESS (6), CYSTIC FIBROSIS FOUNDATION (4), FOOD AND DRUG ADMINISTRATION (1), AND NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH (1). COLLABORATIONS WITH INDUSTRY CONTINUE TO BE AN INTEGRAL PART OF OUR WORK. JCHR WAS ENGAGED IN COLLABORATIONS WITH 14 INDUSTRY PARTNERS SPANNING 21 STUDIES, INCLUDING 11 INVESTIGATOR INITIATED STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), BREAKTHROUGH T1D, HELMSLEY CHARITABLE TRUST, AND ROCHE. JCHR ALSO SELF-FUNDED ONE STUDY AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. AMONG APPROXIMATELY 2,705 ENTITIES RECEIVING NIH FUNDING IN 2025, JCHR RANKS IN THE TOP 8 PERCENT. OUT OF APPROXIMATELY 59,500 NIH GRANTS AWARDED IN 2025, JCHR HAD THE 108TH- (TOP 0.18 PERCENT) AND 202ND - (TOP 0.34 PERCENT) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2025). DURING 2025, JCHR'S RESEARCH EFFORTS FOCUSED ON THREE MAIN THERAPEUTIC AREAS: DIABETES RESEARCH: A MULTITUDE OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES INVOLVED RESEARCH IN TYPE 1, TYPE 2, AND GESTATIONAL DIABETES, ENCOMPASSING PEDIATRIC AND ADULT POPULATIONS INCLUDING MATERNAL-FETAL HEALTH OUTCOMES. MANY STUDIES FOCUSED ON ADVANCING TECHNOLOGY-DRIVEN DIABETES MANAGEMENT WITH ARTIFICIAL PANCREAS SYSTEMS, INSULIN PUMPS, AND CONTINUOUS GLUCOSE MONITORS (CGMS), WHILE OTHERS INVOLVED THE ASSESSMENT OF GROWING ADJUNCT THERAPY USE IN DIABETES CARE AS WELL AS INTERVENTIONAL STRATEGIES TO PRESERVE ENDOGENOUS INSULIN PRODUCTION, UTILIZE INHALED INSULIN, OR LEVERAGE ENHANCED PATIENT AND CAREGIVER EDUCATION INCLUDING AROUND EXERCISE REGIMENS TO IMPROVE GLUCOSE CONTROL. EYE DISEASE RESEARCH: JCHR CONTINUED ITS ROLE AS A COORDINATING CENTER FOR THREE MAJOR NETWORKS AS WELL AS INDIVIDUAL EYE DISEASE STUDIES: 1. THE DRCR RETINA NETWORK, INVESTIGATING DIABETIC RETINOPATHY, AGE-RELATED MACULAR DEGENERATION, AND OTHER RETINAL DISEASES. 2. THE PEDIATRIC EYE DISEASE INVESTIGATOR GROUP (PEDIG), FOCUSING ON A WIDE RANGE OF CHILDHOOD EYE CONDITIONS. 3. THE FOUNDATION FIGHTING BLINDNESS CONSORTIUM, DEDICATED TO STUDYING RARE RETINAL DISEASES. ADDITIONALLY, JCHR IS CURRENTLY COORDINATING A STUDY ON LONG-TERM OUTCOMES FOLLOWING CORNEAL TRANSPLANTATION. CYSTIC FIBROSIS RESEARCH: JCHR'S GROWING RESEARCH PORTFOLIO INCLUDES A TRIAL INVESTIGATING USE OF THE BIONIC PANCREAS SYSTEM TO MANAGE CYSTIC FIBROSIS-RELATED DIABETES AS WELL AS OBSERVATIONAL STUDIES SEEKING TO BETTER CHARACTERIZE OTHER PHYSIOLOGICAL AND METABOLIC COMPLICATIONS OF CYSTIC FIBROSIS. KEY STUDIES EXAMINED THE IMPACT OF NUTRITION, MUSCLE STRENGTH, AND GLUCOSE MONITORING TECHNOLOGIES ON LUNG FUNCTION AND OVERALL HEALTH OUTCOMES IN INDIVIDUALS WITH CYSTIC FIBROSIS.